Tenax Therapeutics is currently in a high-stakes clinical development phase, characterized by a transition from near-insolvency to a more stable liquidity position supported by $118.8 million in cash as of 2026Q1. While the company has successfully bolstered i...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 31, 2026 | -$0.35+8.2% vs -$0.38 | — vs — |
Q2 2026 May 12, 2026 | -$0.35+12.5% vs -$0.40 | — vs — |
Q2 2026 Mar 10, 2026 | -$0.38+69.8% vs -$1.26 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.40+69.9% vs -$1.33 | — vs — |
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress.
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Benchmark TENX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tenax Therapeutics, Inc. (TENX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.90 | $96.65M | -1.42 | — | — | -55.64% | — | |
| $4.34 | $17.12M | -0.18 | — | — | -411.58% | — | |
| $57.66 | $1.91B | -5.93 | -43.89% | -287.84% | -37.99% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $8.68 | $454.43M | -1.92 | -92.84% | -80.67% | -14.98% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — |
Tenax Therapeutics, Inc. (TENX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tenax Therapeutics, Inc. (TENX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 31, 2026·SEC
Jul 2, 2026·SEC
Jun 30, 2026·SEC
Get notified when TENX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tenax Therapeutics, Inc. (TENX) stock FAQ — growth, dividends, profitability & financials explained
Tenax Therapeutics, Inc. (TENX) reported a net loss of $64.9M for fiscal year 2025.
Tenax Therapeutics, Inc. (TENX) has a return on equity (ROE) of -55.6%. Negative ROE indicates the company is unprofitable.
Tenax Therapeutics, Inc. (TENX) had negative free cash flow of $46.0M in fiscal year 2025, likely due to heavy capital investments.
